Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease

Xiaojun Xin1, Xiangming Wang2, Xuesi Dong3, Yuanming Fan4, Wei Shao3, Xiang Lu1 & Pingxi Xiao1

Although percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) and bypass grafting are generally believed to be superior revascularization strategies in patients with coronary artery disease (CAD), the optimal strategy for diabetic patients is still controversial. This meta-analysis was performed to compare two methods of revascularization for patients with diabetes mellitus with left main coronary artery lesions or disease in multiple coronary arteries. Compared with the coronary artery bypass grafting (CABG) group, those receiving PCI-DES showed a greater risk of major adverse cardiovascular events (MACEs) (hazard ratio [HR]: 1.12, 95% confidence interval [CI]: 1.01–1.25, \( P = 0.03 \)), major adverse cardiac and cerebrovascular events (MACCEs) (HR: 1.85, 95% CI: 1.58–2.16; \( P < 0.001 \)), stroke (HR: 1.15, 95% CI: 1.02–1.29, \( P = 0.02 \)), myocardial infarction (MI) (HR: 1.48, 95% CI: 1.04–2.09, \( P = 0.03 \)), and repeat revascularization (HR: 3.23, 95% CI: 1.37–7.59, \( P = 0.007 \)). CABG for diabetic patients with multivessel and/or left main CAD was superior to PCI-DES with regard to MACEs, MACCEs, MI, repeat revascularization and stroke, but there was no clear difference in all-cause mortality.

Diabetic patients with coronary atherosclerotic heart disease often have serious and diffuse atherosclerosis of multiple epicardial coronary arteries1. Correspondingly, it is necessary for an increasing number of diabetic patients with coronary artery disease (CAD) to undergo drug-eluting stenting with bypass grafting2. Diabetes mellitus (DM) is considered a risk factor for a poor prognosis in CAD patients undergoing either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). In addition, it has been reported that patients with DM could have elevated cardiovascular mortality and morbidity rates after revascularization3–6. Although CABG is considered a more appropriate approach to revascularization than PCI in diabetic patients with multivessel coronary disease, it also results in higher rates of adverse cerebral vascular outcomes and perioperative morbidities. Meanwhile, CABG is more invasive than PCI, which causes some patients to choose PCI as a revascularization strategy. Fortunately, with the development of an interventional field, one of the important restrictions on PCI has been substantially reduced. The development of drug-eluting stents (DESs) has clearly decreased the rates of restenosis and repeat revascularizations in comparison with the rates in the previous era of bare metal stents (BMSs)7–10.

To date, a number of clinical trials have compared PCI-DES and CABG in patients with DM and multivessel or left main coronary artery disease11–18. These trials have elucidated the effects of the two methods on the medium- and long-term clinical endpoints. However, the scale of these observational controlled trials (OCTs)
has been small, and some studies were single-centre observational trials. The number of published randomized controlled trials (RCTs) with diabetic patients is currently small.

In summary, there is not powerful evidence to find statistically significant differences with respect to all-cause mortality, major adverse cardiovascular events (MACEs), major adverse cardiac and cerebrovascular events (MACCEs), stroke, repeat revascularization and myocardial infarction (MI) between the PCI and CABG groups. Considering this situation, it is imperative to conduct a quantitative evaluation and synthesis of the current information about the optimal revascularization strategy for these patients.

Results

Study selection and characteristics. After removing duplicates and screening at the title and abstract level, 21 potentially qualified studies were identified (Fig. 1). After full-text assessments, we included six clinical trials involving diabetic patients with CAD\(^1\text{–}^\text{16}\). The 6 eligible articles included 5,013 patients (2,510 patients underwent PCI, and 2,503 patients underwent CABG). The general characteristics of the studies that met the inclusion criteria are summarized in Table 1.

MACE. Compared with patients undergoing CABG, those undergoing PCI-DES experienced more MACEs (HR: 1.12, 95% CI: 1.01–1.25, \(P = 0.03\)). There was low heterogeneity among the studies with respect to the composite endpoints (\(I^2 = 3\%, \, P = 0.38\)) (Figs 2(a) and 3(a)). There was no obvious publication bias with regard to MACEs revealed by either the visual assessment of the funnel plot or the quantitative evaluation with Egger’s test (\(P = 0.31\)) (Figs 4(a) and 5(a)). The sensitivity analysis via a random effects model indicated that the superiority of CABG over PCI was clear, with no statistically significant difference compared with the results of the fixed effects meta-analysis (Table 2).

MACCE. MACCEs were reported in 4 of the 6 included articles. Compared with patients undergoing PCI-DES, those undergoing CABG had significantly fewer MACCEs (HR: 1.85, 95% CI: 1.58–2.16; \(P < 0.001\)). There was moderate heterogeneity (\(I^2 = 31\%, \, P = 0.22\)) among the trials with respect to this outcome as revealed by the forest plot (Fig. 2(b)). This moderate heterogeneity in the trials was largely due to the inclusion of the APPROACH trial, as seen in the Galbraith plot (Fig. 3(b)). After removing the APPROACH trial, an HR of 1.65 (95% CI 1.37–1.99) was obtained through a random effects model for this end point (\(P < 0.001\)) without residual heterogeneity (\(I^2 = 0\%, \, P = 0.75\)) (Table 2). Visual evaluation of the funnel plot and quantitative estimation with Egger’s test (\(P = 0.21\)) indicated no significant publication bias with regard to this endpoint (Figs 4(b) and 5(b)).

All-cause mortality. There was no statistical evidence of a difference in all-cause mortality (HR: 1.22, 95% CI: 0.85–1.77, \(P = 0.29\)) (Fig. 2(c)). Through the heterogeneity analysis, a high degree of heterogeneity was found in the included trials (\(I^2 = 88\%, \, P < 0.001\)) due to the inclusion of the FREEDOM trial or the APPROACH trial according to visual inspection of the Galbraith plot (Fig. 3(c)). When the FREEDOM trial was excluded, the random effects model for all-cause mortality had an HR of 1.44 (95% CI: 1.22–1.70, \(P < 0.001\), \(I^2 = 0\%, \, P = 0.91\))
Table 1. General characteristics of the included studies. Abbreviations: CAD, coronary artery disease; EF, ejection fraction; LVD, left ventricular dysfunction; SES, sirolimus-eluting stent; EES, everolimus-eluting stent; PES, paclitaxel-eluting stent; CABG, coronary artery bypass grafting; *type of the drug-eluting stents is unknown as drug-eluting stents became available in Alberta on a limited basis in 2003 and were more widely available by 2004; †pre-specified subgroup analysis

| Study       | Location or no. of centre(s) | No. of subjects (PCI versus CABG) | Design                  | Follow-up duration | Type of revascularization | Coronary lesions                              |
|-------------|------------------------------|----------------------------------|-------------------------|--------------------|---------------------------|-----------------------------------------------|
| PRECOMBAT   | South Korea 102 versus 90    | randomized controlled study†     | 5 years                 | SES/CABG           | unprotected left main CAD with stenosis of more than 50% |
| SYNTAX      | 85 centres 231 versus 221    | randomized controlled study†     | 5 years                 | PES/CABG           | left main CAD (alone or with 1-, 2-, or 3-vessel disease) or isolated 3-vessel disease |
| FREEDOM     | 140 centres 953 versus 947   | randomized controlled study      | 5 years                 | SES or PES/CABG    | multivessel CAD with stenosis of more than 70% and without left main coronary stenosis |
| EXCEL       | 126 centres 256 versus 249   | randomized controlled study†     | 3 years                 | EES/CABG           | left main CAD with stenosis of more than 50% |
| APPROACH    | Canada 869 versus 869        | prospective cohort study         | 12 years                | DES/CABG           | multivessel CAD (involved 2 or 3 coronary arteries or left main CAD) and LVD (EF < 50%) |
| Luo         | China 99 versus 127          | prospective cohort study         | 3 years                 | SES or PES/CABG    | left main CAD defined as stenosis ≥ 50% (alone or with 1-, 2-, or 3-vessel disease) |

(2Table 2). Studies of all sizes unequally distributed on both sides of the line and expanded past the 95% confidence limits in the funnel plot (Fig. 4(c)), although no publication bias was indicated by the quantitative estimation with Egger’s test (P = 0.41) (Fig. 5(c)). This indicated that there were other reasons causing the asymmetry of the funnel plot.

**Stroke.** Compared with patients undergoing CABG, those undergoing PCI-DES had a higher risk of stroke (HR: 1.15, 95% CI: 1.02–1.29, P = 0.02, I² = 0%) (Fig. 2(d)). There was no publication bias according to the results of Egger’s test (P = 0.24) (Fig. 5(d)) and the visual inspection of the funnel plot (Fig. 4(d)). The sensitivity analysis with a fixed effect model also suggested that the incidence of stroke was higher in the PCI-DES group than in the CABG group (HR: 1.15, 95% CI: 1.02–1.29, P = 0.02) (Table 2).

**Myocardial infarction.** Compared to the CABG group, the PCI group had a higher rate of MI (HR: 1.48, 95% CI: 1.04–2.09, P = 0.03). The moderate heterogeneity (I² = 40%, P = 0.03) with respect to this endpoint among the trials is shown in Fig. 2(e). The heterogeneity was mainly due to the inclusion of the Luo study, according to the Galbraith plot (Fig. 3(e)). Therefore, we performed a sensitivity analysis with a random effects model by excluding the Luo trial. The result (HR: 1.24, 95% CI: 1.12–1.36, P < 0.001, I² = 0%, P = 0.51) (Table 2) was significantly different from the result of the previous analysis, which included the Luo trial. There was no significant publication bias according to the results of Egger’s test (P = 0.07) (Fig. 5(e)) and the funnel plot (Fig. 4(e)).

**Repeat revascularization.** Compared with patients undergoing CABG, those undergoing PCI had a higher risk of repeat revascularization (HR: 3.23, 95% CI: 1.37–7.59, P = 0.007), and there was a high degree of heterogeneity (I² = 95%, P = 0.007) among the trials with respect to this outcome (Fig. 2(f)), which was mainly due to the APPROACH trial and FREEDOM trial according to visual inspection of the Galbraith plot (Fig. 3(f)). After the exclusion of these two trials, a sensitivity analysis with a random effects model yielded an HR of 3.27 (95% CI: 1.71–6.24, P = 0.003) for repeat revascularization with moderate heterogeneity (I² = 28%, P = 0.24) (Table 2). Egger’s test (P = 0.50) (Fig. 5(f)) and inspection of the funnel plot (Fig. 4(f)) indicated that there was no clear publication bias among the trials.

**Discussion**

In this meta-analysis incorporating 5,013 diabetic patients with multivessel and/or left main CAD, compared with patients undergoing PCI-DES, those undergoing CABG had lower incidence rates of MACCEs, MACEs, MIs, strokes and repeat revascularization. However, there was no clear difference between the two groups with regard to all-cause mortality. The observed superiority of CABG to PCI-DES with regard to MACCEs was consistent in all included studies, with little heterogeneity. Meanwhile, we found that compared with patients undergoing CABG, those undergoing PCI had a significantly higher prevalence of MACCEs, with moderate heterogeneity mainly driven by the APPROACH trial. There was no publication bias regarding any clinical endpoint according to Egger’s test.

Furthermore, our study was dominated by two large trials (APPROACH trial and FREEDOM trial), which accounted for 73% of the included patients in this analysis. The first data provided by the APPROACH trial showed that the diabetic population with CAD and left ventricular dysfunction (LVD) benefit from CABG rather than PCI-DES, with an elevated long-term overall survival and reduced prevalence rates of repeat revascularization and MI; no clear difference was found with respect to stroke among the included diabetic patients. Several previous RCTs mainly recruited diabetic patients without LVD or included patients who were non-representative. The APPROACH trial fills this gap in the literature12,13,19,20. The FREEDOM trial is the largest randomized trial comparing PCI and CABG in a population with DM and multivessel disease (MVD). In this trial, we observed that CABG was superior to PCI-DES in diabetic patients; compared with patients undergoing CABG, those undergoing PCI had significantly higher rates of mortality and MI, although they had a decreased incidence of stroke. Meanwhile, we did not detect a significant difference with respect to all-cause mortality in the FREEDOM...
trial\textsuperscript{13}. However, the controversy about the two strategies continued. A subgroup analysis of the SYNTAX trial for patients with DM, LM and/or MVD indicated that an elevated risk of repeat revascularization was present in the diabetic subgroup in the PCI arm (HR: 2.75, 95% CI: 1.78–4.24, \( P < 0.001 \)), and a substantially elevated rate of MI was observed in the PCI subgroup of diabetic patients (HR: 1.62, 95% CI: 0.77–3.41, \( P = 0.20 \)). However, there was no significant difference in MACEs or all-cause mortality in the diabetic subgroup.

### Figure 2.

Forest plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.

| Study  | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI |
|--------|-------------------|-----|--------|---------------------------------|
| EXCEL  | 0.04              | 0.2 | 7.3%   | 1.04 [0.70, 1.54]               |
| FREEDOM | 0.1               | 0.05 | 94.3% | 1.11 [1.00, 1.22]               |
| Luo    | 0.75              | 0.4  | 1.9%   | 2.12 [0.97, 4.64]               |
| SYNTAX | 0.24              | 0.21 | 6.6%   | 1.27 [0.84, 1.92]               |
| Total (95% CI) |                     |     | 100.0% | 1.12 [1.01, 1.25]               |
| Heterogeneity: \( \tau^2 = 0.00; \ Chi^2 = 3.10, df = 3 (P = 0.38); I^2 = 3\% | |
| Test for overall effect: \( Z = 2.14 (P = 0.03) \) | |

| Study  | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI |
|--------|-------------------|-----|--------|---------------------------------|
| SYNTAX | 0.59              | 0.17 | 17.3% | 1.80 [1.29, 2.52]               |
| PRECOMBAT | 0.33             | 0.33 | 5.8%  | 1.39 [0.73, 2.66]               |
| FREEDOM | 0.48              | 0.12 | 28.4% | 1.62 [1.28, 2.04]               |
| APPROCH| 0.73              | 0.07 | 49.9% | 2.08 [1.81, 2.38]               |
| Total (95% CI) |                     |     | 100.0% | 1.85 [1.58, 2.16]               |
| Heterogeneity: \( \tau^2 = 0.01; \ Chi^2 = 4.38, df = 3 (P = 0.22); I^2 = 31\% | |
| Test for overall effect: \( Z = 7.65 (P < 0.00001) \) | |

| Study  | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI |
|--------|-------------------|-----|--------|---------------------------------|
| APPROCH | -0.04             | 0.24 | 5.9%  | 0.96 [0.60, 1.54]               |
| FREEDOM | 0.15              | 0.06 | 93.9% | 1.16 [1.03, 1.31]               |
| Luo    | -0.42             | 0.22 | 0.2%  | 0.66 [0.06, 7.18]               |
| SYNTAX | 0.45              | 0.25 | 21.7% | 1.57 [0.96, 2.65]               |
| Total (95% CI) |                     |     | 100.0% | 1.22 [0.85, 1.77]               |
| Heterogeneity: \( \tau^2 = 0.10; \ Chi^2 = 25.23, df = 3 (P < 0.0001); I^2 = 88\% | |
| Test for overall effect: \( Z = 1.07 (P = 0.29) \) | |

| Study  | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI |
|--------|-------------------|-----|--------|---------------------------------|
| APPROCH | -0.04             | 0.24 | 5.9%  | 0.96 [0.60, 1.54]               |
| FREEDOM | 0.15              | 0.06 | 93.9% | 1.16 [1.03, 1.31]               |
| Luo    | -0.42             | 0.22 | 0.2%  | 0.66 [0.06, 7.18]               |
| SYNTAX | 0.45              | 0.25 | 21.7% | 1.57 [0.96, 2.65]               |
| Total (95% CI) |                     |     | 100.0% | 1.15 [1.02, 1.29]               |
| Heterogeneity: \( \tau^2 = 0.00; \ Chi^2 = 80.80, df = 2 (P = 0.67); I^2 = 0\% | |
| Test for overall effect: \( Z = 2.37 (P = 0.02) \) | |

| Study  | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI |
|--------|-------------------|-----|--------|---------------------------------|
| APPROCH | 0.49              | 0.31 | 21.1% | 1.83 [0.89, 3.00]               |
| FREEDOM | 0.2               | 0.05 | 56.4% | 1.22 [1.11, 1.35]               |
| Luo    | 1.48              | 0.68 | 6.5%  | 4.39 [1.20, 16.02]              |
| SYNTAX | 0.48              | 0.38 | 16.0% | 1.62 [0.77, 3.40]               |
| Total (95% CI) |                     |     | 100.0% | 1.48 [1.04, 2.09]               |
| Heterogeneity: \( \tau^2 = 0.05; \ Chi^2 = 5.03, df = 3 (P = 0.17); I^2 = 40\% | |
| Test for overall effect: \( Z = 2.19 (P = 0.03) \) | |

| Study  | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI |
|--------|-------------------|-----|--------|---------------------------------|
| APPROCH | 1.78              | 0.16 | 27.5% | 5.93 [4.33, 8.11]               |
| FREEDOM | 0.33              | 0.11 | 28.1% | 1.39 [1.12, 1.73]               |
| Luo    | 1.81              | 0.64 | 17.7% | 6.11 [1.74, 21.42]              |
| SYNTAX | 1.01              | 0.22 | 26.7% | 2.75 [1.78, 4.23]               |
| Total (95% CI) |                     |     | 100.0% | 3.23 [1.37, 7.59]               |
| Heterogeneity: \( \tau^2 = 0.66; \ Chi^2 = 58.90, df = 3 (P < 0.00001); I^2 = 95\% | |
| Test for overall effect: \( Z = 2.69 (P = 0.007) \) | |
It is noteworthy that the clinical endpoints after PCI were substantially worse for patients with DM than for patients without DM. In the DM population, atherosclerotic lesions may occur in two or three coronary arteries. Additionally, the typical diffuse atherosclerosis with stenosis in multiple locations could result in a reduced success rate of PCI and an elevated risk of restenosis in diabetic patients\textsuperscript{21}. Meanwhile, multiple stenoses means that two or more stents need to be placed in the coronary arteries. This increases the difficulty of PCI and complicates the surgery. To date, the precise mechanism underlying the inferiority of PCI to CABG in diabetic patients is not clear. However, the greater chance of restenosis after PCI, which leads to repeat revascularization and more aggressive progression of atherosclerosis in segments in which stents are not placed, may in part explain these different revascularization endpoints in diabetic patients\textsuperscript{22–25}.

The presentation of diabetic patients appeared to strengthen the superiority of CABG over PCI. CABG is considered a more appropriate approach to revascularization in patients with DM, LM and MVD. However, in clinical practice, PCI is the preferred initial revascularization strategy for diabetic patients because compared with CABG, it is less invasive, requires a shorter time for recovery and carries lower rates of wound infection, bleeding and arrhythmia. Meanwhile, a clear disadvantage of CABG compared with PCI is the occurrence of complications such as repeat thoracotomy for bleeding, postoperative pneumonia, permanent pacemaker implantation, pleural effusions or ventricular fibrillation, which affect 50% of diabetic patients after CABG\textsuperscript{26}.

Ultimately, the aim of a meta-analysis that combines the results of prior studies is to draw a clear conclusion when previous individual trials were unable to generate convincing results. This study summarized the safety and effectiveness of the two methods of revascularization in diabetic patients. In addition, we compared the two revascularization strategies in observational controlled studies that included real-world patients and RCTs that included selected patients. Meanwhile, in this meta-analysis, it was appropriate to use HRs for the

![Figure 3. Galbraith plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.](https://doi.org/10.1038/s41598-019-43681-x)
time-to-event outcomes, which considered the number and timing of events, and the time until the last follow-up for each patient who has not experienced an event and has therefore been censored. In most previous published meta-analysis, odds ratios (ORs) or relative risks (RRs), which are suitable for analysing dichotomous outcomes, were adopted more frequently, although they are less appropriate than HRs for estimating time-to-event results.

Limitations of the study. We acknowledge several limitations of this meta-analysis. First, there were some inherent biases and limitations, such as publication bias, that existed in two of the OCTs included in our meta-analysis. Considerable heterogeneity among the included trials with respect to both the design characteristics and the effect sizes of each clinical outcome were found in this article. Second, in-depth risk stratification on the basis of patients’ complicity of anatomy was not performed, although the appropriate revascularization strategy changed according to coronary complicity, as indicated in the SYNTAX trial. Finally, we did not perform an analysis of clinical short-term outcomes in our study because it was difficult to comprehensively estimate the safety and effectiveness of the two revascularization methods in the short-term.

Conclusions. PCI-DES was inferior to CABG for diabetic patients with left main CAD and/or MVD with regard to MACEs, MACCEs, MIs, strokes and repeat revascularization. However, no obvious difference was observed in all-cause mortality.

Figure 4. Funnel plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.
Methods

Search strategy. We conducted a literature search in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials for relevant clinical studies from January 2003 to May 2018 without language or publication limitations. Both searches of the title/abstract and Medical Subject Heading terms, including 'left main',

| Analysis performed via a fixed effects model | Outcome (total included patients) | HR (95% CI) | P value | Heterogeneity |
|---------------------------------------------|-----------------------------------|------------|---------|---------------|
| Analysis after excluding APPROACH trial performed via a random effects model | MACE (N = 3083) | 1.12 (1.02, 1.23) | P = 0.02 | I² = 3%, P = 0.38 |
| Analysis after excluding FREEDOM trial performed via a random effects model | Stroke (N = 3864) | 1.15 (1.02, 1.29) | P = 0.02 | I² = 0%, P = 0.67 |
| Analysis after excluding Luo trial performed via a random effects model | MACCE (N = 2544) | 1.65 (1.37, 1.99) | P < 0.001 | I² = 0%, P = 0.75 |
| Analysis after excluding APPROACH and FREEDOM trials performed via a random effects model | All-cause mortality (N = 2416) | 1.44 (1.22, 1.70) | P < 0.001 | I² = 0%, P = 0.91 |
| Analysis after excluding Luo trial performed via a random effects model | MI (N = 4090) | 1.24 (1.12, 1.36) | P < 0.001 | I² = 0%, P = 0.51 |
| Analysis after excluding APPROACH and FREEDOM trials performed via a random effects model | Repeat revascularization (N = 678) | 3.27 (1.71, 6.24) | P = 0.003 | I² = 28%, P = 0.24 |

Table 2. Sensitivity analysis. Abbreviations: HR, hazard ratio; CI, confidence interval; MACE, major adverse cardiovascular events; MACCE, major adverse cardiac and cerebrovascular events.

Figure 5. Egger’s publication bias plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.
‘multivessel disease,’ ‘coronary artery bypass,’ ‘percutaneous coronary intervention,’ ‘drug-eluting stents,’ and ‘diabetes mellitus,’ were used to optimize the search strategy and identify all relevant clinical trials comparing interventional therapy with bypass operation on coronary arteries in a diabetic subgroup. Meanwhile, we identified additional studies through the references of review articles.

End points. The primary end point was the occurrence of MACCEs, which were defined as death from any cause, MI, stroke, or repeat revascularization. MACCEs comprised death from any cause, MI, and stroke. The secondary end points included each MACE component.

Selection criteria. We selected the eligible studies that met the following criteria: 1) clinical trials that included patients with DM and LM and/or MVD; 2) comparison of PCI-DES versus CABG; 3) RCTs, OCTs and accessible articles with pre-established subgroup analyses; and 4) clinical follow-up times equal to or greater than twelve months. Studies were considered ineligible according to the following criteria: 1) DESs were not used during interventional therapy; 2) the number of patients included in each arm was less than 50; and 3) repetitive studies.

Study selection. After removing the duplicate studies, the citations and titles/abstracts of the publications identified by the search strategy were screened independently by two reviewers. The full texts of the studies considered relevant by the two reviewers were then retrieved and reviewed. Disagreements with regard to the inclusion of studies during the full-text review were settled by discussion between the two reviewers.

Data extraction. Available data were extracted from the selected trials by two researchers who worked independently. Disagreements were determined via consensus or by consultation with a third researcher when necessary. The following information was extracted from the eligible studies: the name of the study, location or number of centres, number of patients randomized in each arm, duration of the clinical follow-up, design of research, type of revascularization, and characteristics of the coronary lesions. The following primary clinical outcome events were also extracted: MACCEs, MACEs, MIs, all-cause mortality, repeat revascularization, and stroke. Data were extracted from complete articles, and other relevant literature was used as supplementary materials when the articles were reported in >1 publication. If the relevant outcomes were not provided in the eligible articles, we also attempted to contact the corresponding author by e-mail to obtain the details.

Statistical methods. We meta-analysed all endpoints of the selected articles using HRs with 95% CIs. The overall effect size was estimated via Der Simonian and Laird random effects models. To estimate the heterogeneity, the Cochran Q test with a Mantel–Haenszel test on the basis of the pooled HRs was adopted across the studies. The I^2 statistic was used to assess the between-trial heterogeneity (ensuring the variance across arms was a result of heterogeneity rather than chance). Values of 25%, 50%, and 75% were regarded as low, moderate, and high degrees of heterogeneity on the basis of the I^2 statistic. Galbraith plots were also used as a measure to evaluate the heterogeneity of the publications by graphical means. Meanwhile, we constructed forest plots to graphically show the endpoints in clinical practice. Sensitivity analyses were conducted via fixed effects or random effects models with inverse-variance weighting in our repeated analysis. Funnel plots and Egger's tests were used to visually estimate the publication bias. HRs were converted to a logarithmic scale for the funnel plot. In the absence of publication bias, trials are dispersed equally on both sides of the line that evaluates the natural log of the HR. When P is > 0.05 for Egger's publication bias plot, the included trials were considered to have no publication bias. We used STATA 14 which was purchased by Nanjing medical university school of public health or Reviewer Manager software (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014), where appropriate, to perform the statistical analyses.

References
1. Nicholls, S. J. et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 52, 255–262, https://doi.org/10.1016/j.jacc.2008.03.051 (2008).
2. Smith, S. C. Jr. et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients. Circulation 105, e165–169 (2002).
3. Mathew, V. et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45, 1172–1179, https://doi.org/10.1016/j.jacc.2004.10.075 (2005).
4. Stone, G. W. et al. Diabetes mellitus and the clinical and angiographic outcome after percutaneous transluminal coronary angioplasty. Circulation 91, 979–989 (1995).
5. Suarez, S. A. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 38, 409–414 (2001).
6. Elezi, S. et al. Diabetes mellitus and the clinical and angiographic outcome after percutaneous stent placement. J Am Coll Cardiol 32, 1866–1873 (1998).
7. Stone, G. W. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350, 221–231, https://doi.org/10.1056/NEJMoa032441 (2004).
8. Babapulle, M. N., Joseph, L., Belisle, P., Brophy, J. M. & Eisenberg, M. J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364, 583–591, https://doi.org/10.1016/S0140-6736(04)6850-5 (2004).
9. Hermiller, J. B. et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45, 1172–1179, https://doi.org/10.1016/j.jacc.2004.10.075 (2005).
10. Moussa, I. et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolimus-US-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109, 2273–2278, https://doi.org/10.1161/01.CIR.0000129767.45513.73 (2004).
11. Kappetein, A. P. et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 43, 1006–1013, https://doi.org/10.1093/eurjcts/ezt017 (2013).
12. Nagendran, J. et al. Coronary Artery Bypass Surgery Improves Outcomes in Patients With Diabetes and Left Ventricular Dysfunction. *J Am Coll Cardiol* 71, 819–827. https://doi.org/10.1016/j.jacc.2017.12.024 (2018).

13. Lee, J. H. & Lee, S. W. Strategies for multivessel revascularization in patients with diabetes. *J Comp Eff Res* 2, 231–234. https://doi.org/10.2217/cer.13.21 (2013).

14. Luo, Y. et al. Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting. *Coron Artery Dis* 23, 322–329. https://doi.org/10.1097/MCA.0b013e3283564961 (2012).

15. Ahn, J. M. et al. Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study. *J Am Coll Cardiol* 65, 2198–2206. https://doi.org/10.1016/j.jacc.2015.03.033 (2015).

16. Stone, G. W. et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. *N Engl J Med* 375, 2223–2235. https://doi.org/10.1056/NEJMoa1610227 (2016).

17. Kamaleh, M. et al. Percutaneous coronary intervention versus coronary artery bypass surgery in United States veterans with diabetes. *J Am Coll Cardiol* 61, 808–816. https://doi.org/10.1016/j.jacc.2012.11.044 (2013).

18. Kapur, A. et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDiA (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol* 55, 432–440. https://doi.org/10.1016/j.jacc.2009.10.014 (2010).

19. Serruys, P. W. et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 360, 961–972. https://doi.org/10.1056/NEJMoa0804626 (2009).

20. Weintraub, W. S. et al. Comparative effectiveness of revascularization strategies. *N Engl J Med* 366, 1467–1476. https://doi.org/10.1056/NEJMoa1110717 (2012).

21. Fitchett, D. H., Gupta, M., Farkouh, M. E. & Verma, S. Cardiology Patient Page: coronary artery revascularization in patients with diabetes mellitus. *Circulation* 130, e104–106. https://doi.org/10.1161/CIRCULATIONAHA.113.007968 (2014).

22. Head, S. J. et al. Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. *Eur J Cardiothorac Surg* 41, 535–541. https://doi.org/10.1093/ejcts/ezr105 (2012).

23. West, N. E. et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. *Circulation* 109, 867–873. https://doi.org/10.1161/01.CIR.0000016750.63158.94 (2004).

24. Tada, T. et al. Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from J-Cypher registry. *Am J Cardiol* 107, 1155–1162. https://doi.org/10.1016/j.amjcard.2010.12.013 (2011).

25. Hannan, E. L. et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. *Circulation* 113, 2406–2412. https://doi.org/10.1161/CIRCULATIONAHA.110.612267 (2006).

26. Lee, M. S. et al. Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. *Int J Cardiol* 123, 34–42. https://doi.org/10.1016/j.ijcard.2006.11.103 (2007).

27. Parmar, M. K., Torri, V. & Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med* 17, 2815–2834 (1998).

28. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 8, 16. https://doi.org/10.1186/1745-6215-8-16 (2007).

29. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA* 283, 2008–2012 (2000).

30. Egger, M., Schneider, M. & Davey Smith, G. Spurious precision? *Meta-analysis of observational studies. BMJ* 316, 140–144 (1998).

31. DeRouen, L., N. & Laird, N. Meta-analysis in clinical trials revisited. *Circ Contemp Clin Trials* 45, 139–145. https://doi.org/10.1016/j.cct.2015.09.002 (2015).

32. Melsen, W. G., Bootsma, M. C., Rovers, M. M. & Bonten, M. J. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. *Clin Microbiol Infect* 20, 123–129. https://doi.org/10.1111/1469-0691.12494 (2014).

33. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *BMJ* 327, 557–560. https://doi.org/10.1136/bmj.327.7414.557 (2003).

**Author Contributions**

This study was designed by Pingxi Xiao. The studies were selected by Xiaojun Xin and Yuanming Fan. Data extraction was performed by Xiaojun Xin and Xuesi Dong. Data analysis was conducted by Xiaojun Xin and Xiangming Wang. Data review was performed by Wei Shao and Xiang Lu. The first draft was written by Xiaojun Xin. All authors commented on the first draft and agreed with the final version. Pingxi Xiao is the guarantor of the study.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019